1 Name of Determination

(1) This Determination is the National Health (Prescriber bag supplies) Determination 2012.

(2) This Determination may also be cited as PB 73 of 2012.

2 Commencement

This Determination commences on 1 October 2012.

3 Revocation

PB 103 of 2010 (Determinations — Pharmaceutical benefits supplied by medical practitioners and authorised nurse practitioners) is revoked.

4 Definitions

In this Instrument:

Act means the National Health Act 1953.

authorised midwife has the same meaning as in subsection 84(1) of the Act.

authorised nurse practitioner has the same meaning as in subsection 84(1) of the Act.

prescriber bag supplier in relation to a pharmaceutical benefit means a medical practitioner, authorised midwife or authorised nurse practitioner authorised to supply the pharmaceutical benefit under this Determination.

maximum quantity means maximum quantity or number of units.

pharmaceutical benefit has the same meaning as in subsection 84(1) of the Act.

pharmaceutical benefit has a drug has the same meaning as in subsection 84(1) of the Act.

prescriber bag provisions has the same meaning as in subsection 84(1) of the Act.

5 Pharmaceutical benefits

(1) For subsection 93(1) of the Act, a medical practitioner is authorised to supply a pharmaceutical benefit having a drug in a form mentioned in the Schedule if the initials MP are mentioned for the drug and the form in the column headed ‘Prescriber Bag Supplier’ in the Schedule.

(2) For subsection 93AB(1) of the Act, an authorised nurse practitioner is authorised to supply a pharmaceutical benefit having a drug in a form mentioned in the Schedule if the initials NP are mentioned for the drug and the form in the column headed ‘Prescriber Bag Supplier’ in the Schedule.

Note: A pharmaceutical benefit is a brand of a drug in a form with a manner of administration. The drugs are declared, and the forms, manners of administration and brands are determined, by legislative instrument under subsections 85(2), (3), (5) and (6) of the Act, respectively.

6 Maximum quantity

(1) The maximum quantity of pharmaceutical benefits having a drug in a form mentioned in the Schedule which may be obtained by a prescriber bag supplier in any calendar month is the quantity mentioned for the drug and the form in the Schedule under the column headed ‘Maximum Quantity’.

(2) The maximum quantity may be obtained for one pharmaceutical benefit only having a drug in a form mentioned in a Group during a calendar month.

(3) A quantity, up to the maximum quantity, for a pharmaceutical benefit may be obtained at a particular time only if, at that time, the total quantity of every pharmaceutical benefit having a particular drug in a particular form in the Group, previously obtained in accordance with the prescriber bag provisions of the Act and still in the possession of the supplier, is less than the maximum quantity for a pharmaceutical benefit having that drug in that form.

(4) For this section, a Group is each drug in a form mentioned in the Schedule which has the same number mentioned in the column headed ‘Group Number’.

Schedule Pharmaceutical benefits that may be supplied by prescriber bag suppliers

Group Number	Listed Drug	Form	Prescriber Bag Supplier	Maximum Quantity
1	Adrenaline	Injection 1 mg (as acid tartrate) in 1 mL (1 in 1,000)	MP, NP	5
2	Atropine	Injection containing atropine sulfate 600 micrograms in 1 mL	MP, NP	10
3	Benztropine	Injection containing benztropine mesylate 2 mg in 2 mL	MP, NP	5
4	Benzylpenicillin	Powder for injection 600 mg (as sodium)	MP, NP	10
4	Procaine Penicillin	Injection 1.5 g in disposable syringe	MP, NP	5
5	Benzylpenicillin	Powder for injection 3 g (as sodium)	MP, NP	1
6	Chlorpromazine	Injection containing chlorpromazine hydrochloride 50 mg in 2 mL	MP, NP	10
6	Haloperidol	Injection 5 mg in 1 mL	MP, NP	10
7	Clonazepam	Oral liquid 2.5 mg per mL, 10 mL	MP, NP	1
8	Dexamethasone	Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL	MP, NP	5
8	Hydrocortisone	Injection 100 mg (as sodium succinate) with 2 mL solvent	MP, NP	2
8	Hydrocortisone	Injection 250 mg (as sodium succinate) with 2 mL solvent	MP, NP	1
9	Diazepam	Injection 10 mg in 2 mL	MP, NP	5
10	Diphtheria and tetanus vaccine, adsorbed, diluted for adult use	Injection 0.5 mL in pre-filled syringe	MP, NP	20
11	Frusemide	Injection 20 mg in 2 mL	MP, NP	5
12	Glucagon	Injection set containing glucagon hydrochloride 1 mg (1 I.U.) and 1 mL solvent in disposable syringe	MP, NP	1
13	Glyceryl Trinitrate	Sublingual spray (pump pack) 400 micrograms per dose, 200 doses	MP, NP	1
14	Hyoscine	Injection containing hyoscine butylbromide 20 mg in 1 mL	MP, NP	5
15	Lignocaine	Injection containing lignocaine hydrochloride 100 mg in 5 mL	MP, NP	5
16	Methoxyflurane	Liquid for inhalation 999.9 mg per g, 3 mL (with inhaler)	MP	1
17	Metoclopramide	Injection containing metoclopramide hydrochloride 10 mg in 2 mL	MP, NP	10
17	Prochlorperazine	Injection containing prochlorperazine mesylate 12.5 mg in 1 mL	MP, NP	10
18	Morphine	Injection containing morphine sulfate 15 mg in 1 mL	MP, NP	5
18	Morphine	Injection containing morphine sulfate 30 mg in 1 mL	MP, NP	5
19	Naloxone	Injection containing naloxone hydrochloride 2 mg in 5 mL disposable injection set	MP, NP	2
20	Promethazine	Injection containing promethazine hydrochloride 50 mg in 2 mL	MP, NP	10
21	Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation)	MP, NP	1
21	Salbutamol	Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30	MP, NP	1
22	Salbutamol	Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30	MP, NP	1
23	Terbutaline	Injection containing terbutaline sulfate 500 micrograms in 1mL	MP, NP	5
24	Tramadol	Injection containing tramadol hydrochloride 100 mg in 2 mL	MP, NP	5

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.

See http://www.frli.gov.au